June 18, 2020 09:02 AM EDTUpdated 02:32 PM

As BioMarin’s lead rival wanes, Pfizer and Sangamo post a promising update for hemophilia A gene therapy

Pfizer and its hemophilia A gene therapy partners at Sangamo have posted the latest update on their Phase I/II trial for SB-525 — and it …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Bio­Marin’s lead ri­val wanes, Pfiz­er and Sang­amo post a promis­ing up­date for he­mo­phil­ia A gene ther­a­py